Danaher rises on Street-beating Q2
21 Jul 2022
Shares of DHR were up 7.7% at $275.61 per share in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 1.3%.
The Washington, D.C.-based company posted profits of $1.7 billion, or $2.25 per share, on sales of $7.8 million for the three months ended July 1, 2022, for a 4.9% bottom-line slide on sales growth of 7.4%.
Adjusted to exclude one-time items, earnings per share were $2.76, 41¢ ahead of Wall Street, where analysts were looking for sales of $7.3 billion.
“We are pleased with our strong start to 2022,” Danaher President and CEO Rainer M. Blair said in a news release. “Our teams executed well in a challenging environment to deliver high-single-digit core revenue growth, double-digit adjusted earnings per share growth and $2.0 billion of operating cash flow.
“We were particularly encouraged with the high-single-digit growth in our base business and believe we gained market share across the portfolio.”
Danaher said it now expects third-quarter revenue growth in the high-single-digit percent range for the third quarter, with full-year revenue growth also projected for the high-single-digit percent range.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.